https://www.espn.com/mma/story/_/id/35156934/ontario-bans-ufc-betting-integrity-concerns
Johnson & Johnson’s Janssen Announced Updated Data for Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma; Data Presented at ASCO
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study.
